Abstract
The patient was a 78-year-old woman who suffered from right upper quadrant pain. She was diagnosed as colon cancer with hepatic metastasis. Initial chemotherapy using capecitabine plus oxaliplatin(XELOX)+bevacizumab achieved partial response. After 12 months, XELOX was discontinued due to Grade 3 hand-foot syndrome and peripheral neuropathy. Irinotecan plus oral S-1(a combination of tegafur, 5-chloro-2, 4-dihydroxypyridine, and potassium oxonate)and(IRIS)+bevacizumab were continued as second-line therapy, and her status was maintained as stable disease. XELOX and IRIS regimens do not require catheter placement and long infusion process, providing a great advantage to patients.
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Capecitabine
-
Colonic Neoplasms / drug therapy*
-
Colonic Neoplasms / pathology
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Drug Combinations
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Humans
-
Irinotecan
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / secondary
-
Oxaloacetates
-
Oxonic Acid / administration & dosage
-
Tegafur / administration & dosage
-
Tomography, X-Ray Computed
Substances
-
Drug Combinations
-
Oxaloacetates
-
Deoxycytidine
-
S 1 (combination)
-
Tegafur
-
Oxonic Acid
-
Capecitabine
-
Irinotecan
-
Fluorouracil
-
Camptothecin